Anomalous expression of Thy1 (CD90) in B-cell lymphoma cells and proliferation inhibition by anti-Thy1 antibody treatment
Authors:
- 1 May 2010
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 396 (2) , 329-334
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Correlation Index-Based Responsible-Enzyme Gene Screening (CIRES), a Novel DNA Microarray-Based Method for Enzyme Gene Involved in Glycan BiosynthesisPLOS ONE, 2007
- Aberrant expression of N-acetylglucosaminyltransferase-IVa and IVb (GnT-IVa and b) in pancreatic cancerBiochemical and Biophysical Research Communications, 2006
- Antibody-Targeted Immunotherapy for Treatment of MalignancyAnnual Review of Medicine, 2001
- Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphomaBlood, 1994
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994
- Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomasBlood, 1987
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987
- Mouse Thymic Iso-antigensNature, 1966
- THE AKR THYMIC ANTIGEN AND ITS DISTRIBUTION IN LEUKEMIAS AND NERVOUS TISSUESJournal of Experimental Medicine, 1964
- VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMAThe Lancet, 1964